{"gao_id": "GAO-20-215SP", "published": "2019-12-20T12:00:00Z", "released": "2020-01-21T07:00:00Z", "summary": "Drug companies spend 10 to 15 years bringing a drug to market, often at a high cost. Machine learning could reduce the time and cost by finding new insights in large biomedical or health-related data sets. Machine learning is already used throughout drug development, from discovery to clinical trials. Experts say further advances could be transformative. But a lack of high-quality data hinders its use...", "title": "Artificial Intelligence in Health Care: Benefits and Challenges of Machine Learning in Drug Development [Reissued with revisions on Jan. 31, 2020.]", "topics": ["Human capital management", "Patient care", "Clinical trials", "Workers", "Chemical compounds", "Health care standards", "Technology assessment", "Private sector", "Health Care", "Chemistry", "Drugs"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-20-215sp", "versions": [{"title": "Highlights Page (2 pages)", "url": "https://www.gao.gov/assets/gao-20-215sp-highlights.pdf"}, {"title": "Full Report (86 pages)", "url": "https://www.gao.gov/assets/gao-20-215sp.pdf"}, {"title": "Accessible PDF (86 pages)", "url": "https://www.gao.gov/assets/710/706681.pdf"}]}